Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy

Eliran Moshe Reuven, Shani Leviatan Ben-Arye, Hai Yu, Roberto Duchi, Andrea Perota, Sophie Conchon, Shirley Bachar Abramovitch, Jean Paul Soulillou, Cesare Galli, Xi Chen, Vered Padler-Karavani

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cancer immunotherapy aims to harness the immune system to combat malignant processes. Transformed cells harbor diverse modifications that lead to formation of neoantigens, including aberrantly expressed cell surface carbohydrates. Targeting tumor-associated carbohydrate antigens (TACA) hold great potential for cancer immunotherapy. N-glycolylneuraminic acid (Neu5Gc) is a dietary non-human immunogenic carbohydrate that accumulates on human cancer cells, thereby generating neoantigens. In mice, passive immunotherapy with anti-Neu5Gc antibodies inhibits growth of Neu5Gc-positive tumors. Here, we designed an active cancer vaccine immunotherapy strategy to target Neu5Gc-positive tumors. We generated biomimetic glyconanoparticles using engineered αGal knockout porcine red blood cells to form nanoghosts (NGs) that either express (NG pos ) or lack expression (NG neg ) of Neu5Gc-glycoconjugates in their natural context. We demonstrated that optimized immunization of "human-like" Neu5Gc-deficient Cmah -/- mice with NG pos glyconanoparticles induce a strong, diverse and persistent anti-Neu5Gc IgG immune response. The resulting anti-Neu5Gc IgG antibodies were also detected within Neu5Gc-positive tumors and inhibited tumor growth in vivo. Using detailed glycan microarray analysis, we further demonstrate that the kinetics and quality of the immune responses influence the efficacy of the vaccine. These findings reinforce the potential of TACA neoantigens and the dietary non-human sialic acid Neu5Gc, in particular, as immunotherapy targets.

Original languageEnglish (US)
Pages (from-to)2936-2947
Number of pages12
JournalACS Nano
Volume13
Issue number3
DOIs
StatePublished - Mar 26 2019

Fingerprint

vaccines
Cancer Vaccines
Vaccines
biomimetics
Biomimetics
Tumors
tumors
Tumor-Associated Carbohydrate Antigens
cancer
carbohydrates
Carbohydrates
Immunoglobulin G
Cells
antigens
Antigens
Immunization
antibodies
Antibodies
Glycoconjugates
mice

Keywords

  • biomimetic
  • cancer immunotherapy
  • glycan microarray
  • glyconanoparticle
  • N-glycolylneuraminic acid
  • neoantigen
  • sialic acid

ASJC Scopus subject areas

  • Materials Science(all)
  • Engineering(all)
  • Physics and Astronomy(all)

Cite this

Reuven, E. M., Leviatan Ben-Arye, S., Yu, H., Duchi, R., Perota, A., Conchon, S., ... Padler-Karavani, V. (2019). Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. ACS Nano, 13(3), 2936-2947. https://doi.org/10.1021/acsnano.8b07241

Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. / Reuven, Eliran Moshe; Leviatan Ben-Arye, Shani; Yu, Hai; Duchi, Roberto; Perota, Andrea; Conchon, Sophie; Bachar Abramovitch, Shirley; Soulillou, Jean Paul; Galli, Cesare; Chen, Xi; Padler-Karavani, Vered.

In: ACS Nano, Vol. 13, No. 3, 26.03.2019, p. 2936-2947.

Research output: Contribution to journalArticle

Reuven, EM, Leviatan Ben-Arye, S, Yu, H, Duchi, R, Perota, A, Conchon, S, Bachar Abramovitch, S, Soulillou, JP, Galli, C, Chen, X & Padler-Karavani, V 2019, 'Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy', ACS Nano, vol. 13, no. 3, pp. 2936-2947. https://doi.org/10.1021/acsnano.8b07241
Reuven EM, Leviatan Ben-Arye S, Yu H, Duchi R, Perota A, Conchon S et al. Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. ACS Nano. 2019 Mar 26;13(3):2936-2947. https://doi.org/10.1021/acsnano.8b07241
Reuven, Eliran Moshe ; Leviatan Ben-Arye, Shani ; Yu, Hai ; Duchi, Roberto ; Perota, Andrea ; Conchon, Sophie ; Bachar Abramovitch, Shirley ; Soulillou, Jean Paul ; Galli, Cesare ; Chen, Xi ; Padler-Karavani, Vered. / Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. In: ACS Nano. 2019 ; Vol. 13, No. 3. pp. 2936-2947.
@article{ba4075e2697b4803a087ae40a4132d43,
title = "Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy",
abstract = "Cancer immunotherapy aims to harness the immune system to combat malignant processes. Transformed cells harbor diverse modifications that lead to formation of neoantigens, including aberrantly expressed cell surface carbohydrates. Targeting tumor-associated carbohydrate antigens (TACA) hold great potential for cancer immunotherapy. N-glycolylneuraminic acid (Neu5Gc) is a dietary non-human immunogenic carbohydrate that accumulates on human cancer cells, thereby generating neoantigens. In mice, passive immunotherapy with anti-Neu5Gc antibodies inhibits growth of Neu5Gc-positive tumors. Here, we designed an active cancer vaccine immunotherapy strategy to target Neu5Gc-positive tumors. We generated biomimetic glyconanoparticles using engineered αGal knockout porcine red blood cells to form nanoghosts (NGs) that either express (NG pos ) or lack expression (NG neg ) of Neu5Gc-glycoconjugates in their natural context. We demonstrated that optimized immunization of {"}human-like{"} Neu5Gc-deficient Cmah -/- mice with NG pos glyconanoparticles induce a strong, diverse and persistent anti-Neu5Gc IgG immune response. The resulting anti-Neu5Gc IgG antibodies were also detected within Neu5Gc-positive tumors and inhibited tumor growth in vivo. Using detailed glycan microarray analysis, we further demonstrate that the kinetics and quality of the immune responses influence the efficacy of the vaccine. These findings reinforce the potential of TACA neoantigens and the dietary non-human sialic acid Neu5Gc, in particular, as immunotherapy targets.",
keywords = "biomimetic, cancer immunotherapy, glycan microarray, glyconanoparticle, N-glycolylneuraminic acid, neoantigen, sialic acid",
author = "Reuven, {Eliran Moshe} and {Leviatan Ben-Arye}, Shani and Hai Yu and Roberto Duchi and Andrea Perota and Sophie Conchon and {Bachar Abramovitch}, Shirley and Soulillou, {Jean Paul} and Cesare Galli and Xi Chen and Vered Padler-Karavani",
year = "2019",
month = "3",
day = "26",
doi = "10.1021/acsnano.8b07241",
language = "English (US)",
volume = "13",
pages = "2936--2947",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy

AU - Reuven, Eliran Moshe

AU - Leviatan Ben-Arye, Shani

AU - Yu, Hai

AU - Duchi, Roberto

AU - Perota, Andrea

AU - Conchon, Sophie

AU - Bachar Abramovitch, Shirley

AU - Soulillou, Jean Paul

AU - Galli, Cesare

AU - Chen, Xi

AU - Padler-Karavani, Vered

PY - 2019/3/26

Y1 - 2019/3/26

N2 - Cancer immunotherapy aims to harness the immune system to combat malignant processes. Transformed cells harbor diverse modifications that lead to formation of neoantigens, including aberrantly expressed cell surface carbohydrates. Targeting tumor-associated carbohydrate antigens (TACA) hold great potential for cancer immunotherapy. N-glycolylneuraminic acid (Neu5Gc) is a dietary non-human immunogenic carbohydrate that accumulates on human cancer cells, thereby generating neoantigens. In mice, passive immunotherapy with anti-Neu5Gc antibodies inhibits growth of Neu5Gc-positive tumors. Here, we designed an active cancer vaccine immunotherapy strategy to target Neu5Gc-positive tumors. We generated biomimetic glyconanoparticles using engineered αGal knockout porcine red blood cells to form nanoghosts (NGs) that either express (NG pos ) or lack expression (NG neg ) of Neu5Gc-glycoconjugates in their natural context. We demonstrated that optimized immunization of "human-like" Neu5Gc-deficient Cmah -/- mice with NG pos glyconanoparticles induce a strong, diverse and persistent anti-Neu5Gc IgG immune response. The resulting anti-Neu5Gc IgG antibodies were also detected within Neu5Gc-positive tumors and inhibited tumor growth in vivo. Using detailed glycan microarray analysis, we further demonstrate that the kinetics and quality of the immune responses influence the efficacy of the vaccine. These findings reinforce the potential of TACA neoantigens and the dietary non-human sialic acid Neu5Gc, in particular, as immunotherapy targets.

AB - Cancer immunotherapy aims to harness the immune system to combat malignant processes. Transformed cells harbor diverse modifications that lead to formation of neoantigens, including aberrantly expressed cell surface carbohydrates. Targeting tumor-associated carbohydrate antigens (TACA) hold great potential for cancer immunotherapy. N-glycolylneuraminic acid (Neu5Gc) is a dietary non-human immunogenic carbohydrate that accumulates on human cancer cells, thereby generating neoantigens. In mice, passive immunotherapy with anti-Neu5Gc antibodies inhibits growth of Neu5Gc-positive tumors. Here, we designed an active cancer vaccine immunotherapy strategy to target Neu5Gc-positive tumors. We generated biomimetic glyconanoparticles using engineered αGal knockout porcine red blood cells to form nanoghosts (NGs) that either express (NG pos ) or lack expression (NG neg ) of Neu5Gc-glycoconjugates in their natural context. We demonstrated that optimized immunization of "human-like" Neu5Gc-deficient Cmah -/- mice with NG pos glyconanoparticles induce a strong, diverse and persistent anti-Neu5Gc IgG immune response. The resulting anti-Neu5Gc IgG antibodies were also detected within Neu5Gc-positive tumors and inhibited tumor growth in vivo. Using detailed glycan microarray analysis, we further demonstrate that the kinetics and quality of the immune responses influence the efficacy of the vaccine. These findings reinforce the potential of TACA neoantigens and the dietary non-human sialic acid Neu5Gc, in particular, as immunotherapy targets.

KW - biomimetic

KW - cancer immunotherapy

KW - glycan microarray

KW - glyconanoparticle

KW - N-glycolylneuraminic acid

KW - neoantigen

KW - sialic acid

UR - http://www.scopus.com/inward/record.url?scp=85063498902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063498902&partnerID=8YFLogxK

U2 - 10.1021/acsnano.8b07241

DO - 10.1021/acsnano.8b07241

M3 - Article

C2 - 30840433

AN - SCOPUS:85063498902

VL - 13

SP - 2936

EP - 2947

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 3

ER -